RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence

Charles C. Wykoff; Hidetaka Matsumoto; Mark R. Barakat; Helene Karcher; Anthony Lozama; Andrew Mayhook; Olorunfemi A. Oshagbemi; Olessia Zorina; Tarek S. Hassan; Arshad M. Khanani; Jeffrey S. Heier

doi:10.1097/IAE.0000000000003769

RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence

Charles C. Wykoff, Hidetaka Matsumoto, Mark R. Barakat, Helene Karcher, Anthony Lozama, Andrew Mayhook, Olorunfemi A. Oshagbemi, Olessia Zorina, Tarek S. Hassan, Arshad M. Khanani, Jeffrey S. Heier

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Purpose:Retinal vasculitis or vascular occlusion (RV/RO) have been reported after brolucizumab for neovascular age-related macular degeneration. This systematic literature review evaluated RV/RO events after brolucizumab in real-world practice.Methods:Systematic literature searches identified 89 publications; 19 were included.Results:Publications described 63 patients (70 eyes) with an RV/RO event following brolucizumab. Mean age was 77.6 years and 77.8% of patients were women; 32 eyes (45.7%) received one brolucizumab injection before RV/RO. Mean (range) time to event from last brolucizumab injection was 19.4 (0-63) days, with 87.5% of events occurring within 30 days. Among eyes with preevent and postevent visual acuity (VA) assessments, 22/42 eyes (52.4%) showed unchanged (±0.08 logMAR) or improved vision from last recorded preevent assessment at latest follow-up, whereas 15/42 eyes (35.7%) showed ≥0.30 logMAR (≥15 letters) VA reduction. Patients with no VA loss were on average slightly younger and had a higher proportion of nonocclusive events.Conclusion:Most RV/RO events reported after brolucizumab in early real-world practice occurred in women. Among eyes with VA measurements, approximately half experienced VA loss; overall, about one-third had VA reduction of ≥0.30 logMAR at latest follow-up, with indications of regional variations.

Original language	English (US)
Pages (from-to)	1051-1063
Number of pages	13
Journal	Retina
Volume	43
Issue number	7
DOIs	https://doi.org/10.1097/IAE.0000000000003769
State	Published - Jul 1 2023

Keywords

anti-vascular endothelial growth factor therapy
brolucizumab
intraocular inflammation
neovascular age-related macular degeneration
real-world evidence
retinal vascular occlusion
retinal vasculitis
Humans
Retinal Vasculitis/chemically induced
Male
Macular Degeneration/drug therapy
Antibodies, Monoclonal, Humanized/adverse effects
Aged, 80 and over
Female
Aged

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1097/IAE.0000000000003769

Cite this

Wykoff, C. C., Matsumoto, H., Barakat, M. R., Karcher, H., Lozama, A., Mayhook, A., Oshagbemi, O. A., Zorina, O., Hassan, T. S., Khanani, A. M., & Heier, J. S. (2023). RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence. Retina, 43(7), 1051-1063. https://doi.org/10.1097/IAE.0000000000003769

Wykoff, CC, Matsumoto, H, Barakat, MR, Karcher, H, Lozama, A, Mayhook, A, Oshagbemi, OA, Zorina, O, Hassan, TS, Khanani, AM & Heier, JS 2023, 'RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence', Retina, vol. 43, no. 7, pp. 1051-1063. https://doi.org/10.1097/IAE.0000000000003769

@article{923414cd65734127bbc8584d95116c30,

title = "RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence",

abstract = "Purpose:Retinal vasculitis or vascular occlusion (RV/RO) have been reported after brolucizumab for neovascular age-related macular degeneration. This systematic literature review evaluated RV/RO events after brolucizumab in real-world practice.Methods:Systematic literature searches identified 89 publications; 19 were included.Results:Publications described 63 patients (70 eyes) with an RV/RO event following brolucizumab. Mean age was 77.6 years and 77.8% of patients were women; 32 eyes (45.7%) received one brolucizumab injection before RV/RO. Mean (range) time to event from last brolucizumab injection was 19.4 (0-63) days, with 87.5% of events occurring within 30 days. Among eyes with preevent and postevent visual acuity (VA) assessments, 22/42 eyes (52.4%) showed unchanged (±0.08 logMAR) or improved vision from last recorded preevent assessment at latest follow-up, whereas 15/42 eyes (35.7%) showed ≥0.30 logMAR (≥15 letters) VA reduction. Patients with no VA loss were on average slightly younger and had a higher proportion of nonocclusive events.Conclusion:Most RV/RO events reported after brolucizumab in early real-world practice occurred in women. Among eyes with VA measurements, approximately half experienced VA loss; overall, about one-third had VA reduction of ≥0.30 logMAR at latest follow-up, with indications of regional variations.",

keywords = "anti-vascular endothelial growth factor therapy, brolucizumab, intraocular inflammation, neovascular age-related macular degeneration, real-world evidence, retinal vascular occlusion, retinal vasculitis, Humans, Retinal Vasculitis/chemically induced, Male, Macular Degeneration/drug therapy, Antibodies, Monoclonal, Humanized/adverse effects, Aged, 80 and over, Female, Aged",

author = "Wykoff, {Charles C.} and Hidetaka Matsumoto and Barakat, {Mark R.} and Helene Karcher and Anthony Lozama and Andrew Mayhook and Oshagbemi, {Olorunfemi A.} and Olessia Zorina and Hassan, {Tarek S.} and Khanani, {Arshad M.} and Heier, {Jeffrey S.}",

note = "Funding Information: H. Matsumoto is funded by Japan Society for the Promotion of Science KAKENHI (grant number JP 21K09672) and has received personal compensation from Bayer (Japan), Novartis (Japan), Santen (Japan), and Senju (Japan). Funding Information: M. R. Barakat reports personal fees from Alcon (Fort Worth, TX), Alimera (Alpharetta, GA), Allegro Ophthalmics (San Juan Capistrano, CA), Allergan (Irvine, CA), Bausch + Lomb (Bridgewater, NJ), Ocular Therapeutix (Bedford, MA), Palatin Technologies (Cranbury, NJ) and Regeneron (Tarrytown, NY); personal fees and grants from Adverum Biotechnologies (Redwood City, CA), Clearside Biomedical (Alpharetta, GA), EyePoint Pharmaceuticals (Watertown, MA), Genentech (South San Francisco, CA), Graybug Vision (Redwood City, CA), Kodiak Sciences (Palo Alto, CA), Novartis (East Hanover, NJ) and REGENXBIO (Rockville, MD); grants from Annexon Biosciences (Brisbane, CA), Gyroscope Therapeutics (San Francisco, CA), ReNeuron (Bridgend, UK), Ribomic (Berkeley, CA), Stealth Biotherapeutics (Needham, MA), and Unity Biotechnology (South San Francisco, CA); equity in NeuBase (Pittsburgh, PA); and equity in and grants from Oxurion (Iselin, NJ). Publisher Copyright: {\textcopyright} 2023 Lippincott Williams and Wilkins. All rights reserved.",

year = "2023",

month = jul,

day = "1",

doi = "10.1097/IAE.0000000000003769",

language = "English (US)",

volume = "43",

pages = "1051--1063",

journal = "Retina",

issn = "0275-004X",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

T2 - A Systematic Review of Real-World Evidence

AU - Wykoff, Charles C.

AU - Matsumoto, Hidetaka

AU - Barakat, Mark R.

AU - Karcher, Helene

AU - Lozama, Anthony

AU - Mayhook, Andrew

AU - Oshagbemi, Olorunfemi A.

AU - Zorina, Olessia

AU - Hassan, Tarek S.

AU - Khanani, Arshad M.

AU - Heier, Jeffrey S.

N1 - Funding Information: H. Matsumoto is funded by Japan Society for the Promotion of Science KAKENHI (grant number JP 21K09672) and has received personal compensation from Bayer (Japan), Novartis (Japan), Santen (Japan), and Senju (Japan). Funding Information: M. R. Barakat reports personal fees from Alcon (Fort Worth, TX), Alimera (Alpharetta, GA), Allegro Ophthalmics (San Juan Capistrano, CA), Allergan (Irvine, CA), Bausch + Lomb (Bridgewater, NJ), Ocular Therapeutix (Bedford, MA), Palatin Technologies (Cranbury, NJ) and Regeneron (Tarrytown, NY); personal fees and grants from Adverum Biotechnologies (Redwood City, CA), Clearside Biomedical (Alpharetta, GA), EyePoint Pharmaceuticals (Watertown, MA), Genentech (South San Francisco, CA), Graybug Vision (Redwood City, CA), Kodiak Sciences (Palo Alto, CA), Novartis (East Hanover, NJ) and REGENXBIO (Rockville, MD); grants from Annexon Biosciences (Brisbane, CA), Gyroscope Therapeutics (San Francisco, CA), ReNeuron (Bridgend, UK), Ribomic (Berkeley, CA), Stealth Biotherapeutics (Needham, MA), and Unity Biotechnology (South San Francisco, CA); equity in NeuBase (Pittsburgh, PA); and equity in and grants from Oxurion (Iselin, NJ). Publisher Copyright: © 2023 Lippincott Williams and Wilkins. All rights reserved.

PY - 2023/7/1

Y1 - 2023/7/1

N2 - Purpose:Retinal vasculitis or vascular occlusion (RV/RO) have been reported after brolucizumab for neovascular age-related macular degeneration. This systematic literature review evaluated RV/RO events after brolucizumab in real-world practice.Methods:Systematic literature searches identified 89 publications; 19 were included.Results:Publications described 63 patients (70 eyes) with an RV/RO event following brolucizumab. Mean age was 77.6 years and 77.8% of patients were women; 32 eyes (45.7%) received one brolucizumab injection before RV/RO. Mean (range) time to event from last brolucizumab injection was 19.4 (0-63) days, with 87.5% of events occurring within 30 days. Among eyes with preevent and postevent visual acuity (VA) assessments, 22/42 eyes (52.4%) showed unchanged (±0.08 logMAR) or improved vision from last recorded preevent assessment at latest follow-up, whereas 15/42 eyes (35.7%) showed ≥0.30 logMAR (≥15 letters) VA reduction. Patients with no VA loss were on average slightly younger and had a higher proportion of nonocclusive events.Conclusion:Most RV/RO events reported after brolucizumab in early real-world practice occurred in women. Among eyes with VA measurements, approximately half experienced VA loss; overall, about one-third had VA reduction of ≥0.30 logMAR at latest follow-up, with indications of regional variations.

AB - Purpose:Retinal vasculitis or vascular occlusion (RV/RO) have been reported after brolucizumab for neovascular age-related macular degeneration. This systematic literature review evaluated RV/RO events after brolucizumab in real-world practice.Methods:Systematic literature searches identified 89 publications; 19 were included.Results:Publications described 63 patients (70 eyes) with an RV/RO event following brolucizumab. Mean age was 77.6 years and 77.8% of patients were women; 32 eyes (45.7%) received one brolucizumab injection before RV/RO. Mean (range) time to event from last brolucizumab injection was 19.4 (0-63) days, with 87.5% of events occurring within 30 days. Among eyes with preevent and postevent visual acuity (VA) assessments, 22/42 eyes (52.4%) showed unchanged (±0.08 logMAR) or improved vision from last recorded preevent assessment at latest follow-up, whereas 15/42 eyes (35.7%) showed ≥0.30 logMAR (≥15 letters) VA reduction. Patients with no VA loss were on average slightly younger and had a higher proportion of nonocclusive events.Conclusion:Most RV/RO events reported after brolucizumab in early real-world practice occurred in women. Among eyes with VA measurements, approximately half experienced VA loss; overall, about one-third had VA reduction of ≥0.30 logMAR at latest follow-up, with indications of regional variations.

KW - anti-vascular endothelial growth factor therapy

KW - brolucizumab

KW - intraocular inflammation

KW - neovascular age-related macular degeneration

KW - real-world evidence

KW - retinal vascular occlusion

KW - retinal vasculitis

KW - Humans

KW - Retinal Vasculitis/chemically induced

KW - Male

KW - Macular Degeneration/drug therapy

KW - Antibodies, Monoclonal, Humanized/adverse effects

KW - Aged, 80 and over

KW - Female

KW - Aged

UR - http://www.scopus.com/inward/record.url?scp=85163124165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85163124165&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000003769

DO - 10.1097/IAE.0000000000003769

M3 - Review article

C2 - 36893438

AN - SCOPUS:85163124165

SN - 0275-004X

VL - 43

SP - 1051

EP - 1063

JO - Retina

JF - Retina

IS - 7

ER -

RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this